Feb 25, 2009 - Alexion Pharmaceuticals, Inc., today announced that the Australian Government's Therapeutic Goods Administration has approved the use of Soliris (eculizumab) for the treatment of all patients in Australia with paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis. Soliris is the first therapy approved in Australia for the treatment of PNH.
the details can be read here.
No comments:
Post a Comment